Archived NCCN Tumor Boards: Exploring Omission of Radiation Therapy in the Management of Rectal Cancer

The optimal treatment plan for a patient with locally advanced rectal cancer can be challenging for providers to determine since there are several different approaches to neoadjuvant treatment which may be considered based on clinical characteristics, patient preferences, and response to treatment. Education on de-escalation of radiation therapy for rectal cancer will highlight the most current clinical trial data and help clinicians identify which patients would be the best candidates for this new approach.

Target Audience

This program is designed to meet the educational needs of physicians/oncologists, nurse practitioners, nurses, physician associates, pharmacists, and other health care professionals who manage patients with cancer.

Learning Objectives

Following this activity, participants should be able to:

  • Discuss the results of recent clinical trials looking at omission of radiation therapy in neoadjuvant treatment of rectal cancer. 
  • Describe how these results may be integrated into clinical practice for treatment of locally advanced rectal cancer. 
  • Define the characteristics of a patient with rectal cancer who is a good candidate for omission of radiation therapy.

You may also be interested in

Recorded Presentation from the NCCN Pharmacy Updates: Advances in Neoadjuvant Treatment Options in Locally Advanced and Metastatic Rectal Cancer with Deficient Mismatch Repair
Treatment options for locally advanced or metastatic rectal cancer are evolving constantly. It is important for care teams to have an understanding of the current treatment approaches, toxicity management, and appropriate supportive care recommendations throughout a patient’s treatment course.
Team-Based Case Review: Oligometastatic Prostate, Non-Small Cell Lung, and Colorectal Cancers
The role of metastasis-directed therapy (MDT) for patients with oligometastatic cancer is rapidly evolving, and trials have shown that integrating metastasis-directed therapy into the care of these patients can improve oncologic outcomes including time to disease progression and overall survival.
Additional information
Supporters: 

This activity is supported by educational grants from:

  • AstraZeneca
  • Azurity Pharmaceuticals
  • Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC
  • Novartis

This activity is supported by an independent medical education grant from AbbVie.

This activity is supported through an independent educational grant from Merck & Co., Inc., Rahway, NJ, USA.

Course summary
Available credit: 
  • 1.00 AAPA Category 1 CME credit
  • 1.00 ACPE contact hours
  • 1.00 AMA PRA Category 1 Credit™
  • 1.00 ANCC contact hours
  • 1.00 CCM clock hours
  • 1.00 Participation
Course opens: 
09/26/2025
Course expires: 
09/16/2026
Cost:
$0.00

Tiago Biachi de Castria, MD, PhD
Moffitt Cancer Center

Sarah E. Hoffe, MD
Moffitt Cancer Center

Seth Felder, MD
Moffitt Cancer Center

 

NCCN Continuing Education Disclosure Policy
It is the policy of NCCN that all planners, faculty, moderators, authors, reviewers and anyone involved in the planning and delivery of NCCN continuing education activities are expected to disclose ALL financial relationships they have had in the past 24 months with ineligible companies. The ACCME Standards for Integrity and Independence require that individuals who refuse to provide this information will be disqualified from involvement in the planning and implementation of accredited continuing education presented by NCCN. NCCN identifies, mitigates and discloses to learners all relevant financial relationships.

In addition, all content has been reviewed to ensure education promotes safe, effective patient care and does not promote the products or services of an ineligible company. Content, including any presentation of therapeutic options, is fair, balanced, evidence-based, scientifically accurate, and free of commercial bias and marketing. 

Definitions  

Ineligible Company: An ineligible company is any entity whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients. 

Relevant Financial Relationships: Financial relationships of any dollar amount occurring within the past 24 months are defined as relevant if the educational content an individual can control is related to the business lines or products of an ineligible company. There is no minimum financial threshold. We ask for disclosure of ALL financial relationships with ineligible companies, regardless of the amount and regardless of the potential relevance of each relationship to the education.

Faculty Disclaimers  

All faculty for this continuing education activity are competent in the subject matter and qualified by experience, training, and/or preparation for the tasks and methods of delivery.

Faculty presentations may include discussion of off-label use. Faculty will disclose that the use in question is not currently approved by the FDA per the product labeling or marketing.

Faculty Disclosures

The faculty listed below have no financial relationships with ineligible companies to disclose.

Seth Felder, MD

The faculty listed below have the following relevant financial relationship(s) with ineligible companies to disclose. All of the relevant financial relationships listed for these individuals have been mitigated.

Tiago Biachi de Castria, MD, PhD
A2 Biotherapeutics, Inc.: Scientific Advisor
Astellas Pharma US, Inc.: Grant/Research Support
AstraZeneca Pharmaceuticals LP: Honoraria; Product/Speakers Bureau; Scientific Advisor
Bayer HealthCare: Scientific Advisor
Ipsen: Grant/Research Support
Moderna, Inc.: Honoraria

Sarah E. Hoffe, MD
MyCareGorithm: Officer, Director or any Other Fiduciary Role

NCCN Staff Disclosures

None of the planners for this educational activity have relevant financial relationships to disclose with ineligible companies whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.

image

In support of improving patient care, National Comprehensive Cancer Network (NCCN) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Physicians
NCCN designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Nurses
NCCN designates this educational activity for a maximum of 1.0 contact hour.

Pharmacists
NCCN designates this knowledge-based continuing education activity for 1.0 contact hour (0.10 CEUs) of continuing education credit. UAN: JA4008196-0000-25-118-H01-P

Physician Associates
NCCN has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 1.0 AAPA Category 1 CME credit. Approval is valid until September 16, 2026. PAs should only claim credit commensurate with the extent of their participation.

Case Managers
This program has been pre-approved by The Commission for Case Manager Certification to provide continuing education credit to CCM® board certified case managers. The course is approved for 1 CE contact hour. Activity Code: S00064167; Approval #: 250002462

Available Credit

  • 1.00 AAPA Category 1 CME credit
  • 1.00 ACPE contact hours
  • 1.00 AMA PRA Category 1 Credit™
  • 1.00 ANCC contact hours
  • 1.00 CCM clock hours
  • 1.00 Participation

Price

Cost:
$0.00
Please login or register to take this course.

Required Hardware/software

To complete this activity, users will need:

  • A device with an Internet connection and sound playback capability
    • One of the two latest versions of Google Chrome, Mozilla Firefox, or Safari
    • Internet Explorer is no longer supported
  • Adobe Reader or other PDF reader software for certificate viewing/printing